The primary endpoint of SELECT-AXIS 1: ASAS40 response for RINVOQ vs placebo at Week 14 was met.
ASAS40 with RINVOQ vs placebo at Week 14 was the primary endpoint, all other data shown were prespecified non-ranked non-multiplicity-controlled endpoints.
DATA LIMITATIONS: Data not labelled as a primary or ranked secondary endpoint were prespecified non-ranked endpoints not controlled for multiplicity with nominal p-values; therefore, treatment differences could represent chance findings. No conclusions regarding these comparisons can be made. Non-responder imputation: Patients dropping out of the study for any reason were considered non-responders.
*p<0.001 vs placebo, comparison adjusted for multiplicity. ‡Nominal p<0.001 vs placebo, comparison not adjusted for multiplicity.